Buscar resultados de ensayos clínicos
Paragangliomas 1 - 25 Studies Found
Estado | Estudiar |
Terminated |
Nombre del estudio: Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma Condición:
Fecha: 2009-05-29 |
Completed |
Nombre del estudio: Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Condición:
Fecha: 2009-02-12 Intervenciones: Drug: Sunitinib 50 mg oral dose daily for 4 weeks, 2 week rest period (repeating 6 week cycles) |
Recruiting |
Nombre del estudio: First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma Condición: Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL) Fecha: 2011-06-09 Intervenciones:
|
Active, not recruiting |
Nombre del estudio: Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation Condición:
Fecha: 2014-06-04 Intervenciones: Other: PET-CT |
Completed |
Nombre del estudio: Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Condición:
Fecha: 2007-04-09 Intervenciones: Drug: Ultratrace Iobenguane (MIBG) I 131 Phase I: Dose escalation protocol Phase II: Treatment schedule |
Active, not recruiting |
Nombre del estudio: A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Condición:
Fecha: 2009-04-01 Intervenciones: Radiation: Ultratrace® Iobenguane I131 Each subject will be administered 3 mCi to 6 mCi Ultratrace& |
Available |
Nombre del estudio: Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Condición:
Fecha: 2016-11-08 Intervenciones: Drug: Ultratrace Iobenguane I131 Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 who |
Active, not recruiting |
Nombre del estudio: Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Condición:
Fecha: 2013-10-19 Intervenciones: Drug: Axitinib (AG-013736) Axitinib will be given as self-administered oral doses at the initial level o |
Withdrawn |
Nombre del estudio: Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma Condición:
Fecha: 2013-09-10 Intervenciones:
|
Not yet recruiting |
Nombre del estudio: Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Condición:
|